Constipation-Predominant Irritable Bowel Syndrome Clinical Trial Pipeline Highlights, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Constipation-Predominant Irritable Bowel Syndrome Clinical Trial
Pipeline Highlights – 2019” report has been added to ResearchAndMarkets.com’s
offering.

Constipation-Predominant Irritable Bowel Syndrome Pipeline Highlights –
2019, provides most up-to-date information on key pipeline products in
the global Constipation-Predominant Irritable Bowel Syndrome market. It
covers emerging therapies for Constipation-Predominant Irritable Bowel
Syndrome in active clinical development stages including early and late
stage clinical trials. The pipeline data presented in this report helps
executives for tracking competition, identifying partners, evaluating
opportunities, formulating business development strategies, and
executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Constipation-Predominant Irritable Bowel Syndrome
pipeline products by clinical trial stages including both early and late
stage development – phase 3 clinical trials, phase 2 clinical trials,
phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Constipation-Predominant Irritable Bowel Syndrome
pipeline products by their dominant mechanism of action/drug class. This
helps executives categorize products based on their drug class and also
assess the strengths and weaknesses of compounds.

Company:

The report provides Constipation-Predominant Irritable Bowel Syndrome
pipeline products by the company.

Short-term Launch Highlights:

Find out which Constipation-Predominant Irritable Bowel Syndrome
pipeline products will be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Constipation-Predominant Irritable Bowel Syndrome Pipeline by Stages

2. Constipation-Predominant Irritable Bowel Syndrome Phase 3 Clinical
Trial Insights

3. Constipation-Predominant Irritable Bowel Syndrome Phase 2 Clinical
Trial Insights

4. Constipation-Predominant Irritable Bowel Syndrome Phase 1 Clinical
Trial Insights

5. Constipation-Predominant Irritable Bowel Syndrome Preclinical
Research Insights

6. Constipation-Predominant Irritable Bowel Syndrome Discovery Stage
Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/5x6yu9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Gastrointestinal
Drugs